Department of Health and Social Care

The UK National Screening Committee (UK NSC) advises ministers and the National Health Service in the four nations of the United Kingdom about all aspects of screening. The implementation of any UK NSC screening recommendation is a devolved matter.

The Government has recognised that, nationally, demand for assessments for attention deficit hyperactivity disorder (ADHD) has grown significantly in recent years and that people are experiencing severe delays for accessing such assessments. The Government’s 10-Year Health Plan will make the National Health Service fit for the future and recognises the need for early intervention and support.

For the first time, NHS England published management information on ADHD assessment waiting times at a national level on 29 May 2025 as part of its ADHD data improvement plan. Data is now released each quarter with the latest release in August 2025.

Data on ADHD waiting times at an integrated care board (ICB) level is not currently held centrally. NHS England has released technical guidance to ICBs to improve the recording of ADHD data, with a view to improving data quality and publishing more localised data. NHS England intends to publish data at an ICB level in 2026/27.

My Rt Hon. Friend, the Secretary of State for Health and Social Care, announced on 4 December the launch of an Independent Review into Prevalence and Support for Mental Health Conditions, ADHD, and Autism. This independent review will inform our approach to enabling people with ADHD to have the right support in place to enable them to live well in their communities.

Advocacy services play an important role in helping patients' voices to be heard and in ensuring their legal rights are protected. Guidance issued by the National Institute for Health and Care Excellence indicates that advocacy can provide several benefits, including helping to uphold individuals’ rights, supporting vulnerable individuals, involvement in decision-making, and promoting continuity of care.

There are several different types of patient advocacy services, and it is for local commissioning bodies to plan and commission advocacy services, in line with relevant legislation.

Specifically on complaints advocacy services, whilst National Health Service organisations must have their own complaints procedures, they are not required to provide complaints advocacy services. The legal duty to provide this service rests with local authorities, who are required by the Health and Social Care Act 2012 to make arrangements for the provision of independent advocacy services in their area. Each year the Government provides approximately £15 million of grant funding to local authorities towards this service.

Advocacy services play an important role in helping patients' voices to be heard and in ensuring their legal rights are protected. Guidance issued by the National Institute for Health and Care Excellence indicates that advocacy can provide several benefits, including helping to uphold individuals’ rights, supporting vulnerable individuals, involvement in decision-making, and promoting continuity of care.

There are several different types of patient advocacy services, and it is for local commissioning bodies to plan and commission advocacy services, in line with relevant legislation.

Specifically on complaints advocacy services, whilst National Health Service organisations must have their own complaints procedures, they are not required to provide complaints advocacy services. The legal duty to provide this service rests with local authorities, who are required by the Health and Social Care Act 2012 to make arrangements for the provision of independent advocacy services in their area. Each year the Government provides approximately £15 million of grant funding to local authorities towards this service.

Advocacy services play an important role in helping patients' voices to be heard and in ensuring their legal rights are protected. Guidance issued by the National Institute for Health and Care Excellence indicates that advocacy can provide several benefits, including helping to uphold individuals’ rights, supporting vulnerable individuals, involvement in decision-making, and promoting continuity of care.

There are several different types of patient advocacy services, and it is for local commissioning bodies to plan and commission advocacy services, in line with relevant legislation.

Specifically on complaints advocacy services, whilst National Health Service organisations must have their own complaints procedures, they are not required to provide complaints advocacy services. The legal duty to provide this service rests with local authorities, who are required by the Health and Social Care Act 2012 to make arrangements for the provision of independent advocacy services in their area. Each year the Government provides approximately £15 million of grant funding to local authorities towards this service.

Following a request from the Department, the Joint Committee on Vaccination and Immunisation (JCVI) briefly discussed the emerging evidence on the link between shingles vaccination and dementia in its June 2025 meeting.

It was noted that results were consistent across different vaccines and different observational studies and had some potential biological plausibility. However, based on currently available data, this possible benefit was not quantifiable due to the high chance of bias in many of these observational studies.

For these reasons, no change to the current JCVI recommendation on shingles vaccination could be advised at this time. The JCVI continues to monitor emerging evidence relating to all immunisation programmes, including on the potential link between shingles vaccination and dementia, keeping its advice under review.

Answering this question would require Medicines and Healthcare products Regulatory Agency staff to go through a vast volume of protocol documents manually. This is because the information is not held in such a way to be able to filter electronically by the requested category.

The Guide to Parliamentary Work sets out that there is an advisory cost limit known as the disproportionate cost threshold which is the level above which departments can decide not to answer a written question. The current disproportionate cost threshold is £850.

The Guide to Parliamentary Work is published online and is available on the GOV.UK website.

The 10-Year Health Plan recognises that there is more that can be done to improve timely diagnosis closer to the patient’s home. The plan’s commitment to the three big shifts, and the further development of facilities such as community diagnostic centres, are central to delivering the Government’s commitment to achieve a 25% reduction in premature mortality due to cardiovascular disease and stroke across England, including people with arrythmias. For further information, a copy of our plan Reforming elective care for patients is attached.

The use of novel digital health and technology, such as non-invasive ambulatory electrocardiogram monitoring in the community, will facilitate the earlier diagnosis and treatment of conditions such as cardiac arrythmias and atrial fibrillation.

Whilst it would not be appropriate for ministers to comment on individual cases, the Government is clear that bullying is unacceptable in any workplace and has no place in the National Health Service. All employers across the NHS should have a robust policy on bullying outlining how it should be handled and the support available to staff.

NHS England has developed an NHS Civility and Respect programme which provides national guidance, training, and resources to help organisations build positive workplace cultures, tackle bullying and harassment, and ensure staff feel safe and supported in all work environments.

NHS staff should have the confidence to speak out and come forward if they have concerns. There is support in place for staff who wish to raise concerns, including a network of more than 1,200 local Freedom to Speak Up Guardians across healthcare in England, whose role is to help and support NHS workers.

We intend to engage with a range of partners over the coming months to enable us to build a modern service framework which is both ambitious and practical, to ensure we can improve system performance for people with dementia and frailty both now and in the future.

No specific individuals or organisations have been appointed at this time. However, we intend to formalise a governance structure for the development of the modern service framework shortly which we will share with partners in due course.

To reduce the risks of sudden cardiac death, NHS England has published a national service specification for inherited cardiac conditions which includes services for young adults with previously undiagnosed cardiac disease.

NHS England is currently reviewing this service specification and is working with a broad range of stakeholders as part of the review.

External engagement is a fundamental part of what United Kingdom ministerial Government departments do.  We recognise the importance of promoting transparency through engagement and the need to take a balanced and proportionate approach.

In Fit for the Future: 10-Year Health Plan for England, the Government has committed to some crucial steps to help people make healthier choices about alcohol, for instance making it a legal requirement for alcohol labels to display health warnings and consistent nutritional information. The plan can be accessed online at the following link:

https://www.gov.uk/government/publications/10-year-health-plan-for-england-fit-for-the-future

In the development and progression of the 10-Year Health Plan’s commitments and other policies, Department officials have met a wide range of stakeholders and are making plans for further stakeholder engagement to take place shortly. Stakeholder insights will help shape the Department’s work to ensure that are policies are most effective.

The Department does not hold data on the number of neurologists or geriatricians with specialist training in Parkinson’s disease, nor does NHS England publish workforce projections at this level of granularity. Neurologists typically manage a wide range of conditions, including Parkinson’s, and geriatricians are trained to manage a broad range of complex health needs in older people. Workforce data is collected for the specialty as a whole rather than by sub-specialty.

As of August 2025, there were 2,010 full-time equivalent (FTE) doctors working in the specialty of neurology and 6,284 in geriatric medicine in National Health Service trusts and other organisations in England. This includes 1,025 FTE consultant neurologists and 1,687 FTE consultant geriatricians.

The Department does not hold specific data on the number of specialist Parkinson’s nurses currently working in the NHS in England. These roles are commissioned and managed locally by NHS trusts and integrated care boards (ICBs) as part of neurology and movement disorder services.

NHS England uses workforce modelling to establish potential future scenarios for both the supply of, and demand for, NHS workers across all specialties. In doing so, they analyse a range of factors, including population health trends, service utilisation patterns, and projected retirement and training rates. This modelling helps determine the number of training places required and informs long-term workforce planning, ensuring that specialties such as neurology and geriatric medicine have sufficient capacity to meet anticipated needs.

The Government will publish a 10 Year Workforce Plan to set out action to create a workforce ready to deliver the transformed service set out in the 10-Year Health Plan. It will ensure that the NHS has the right people in the right places, with the right skills to care for patients, including those with Parkinson’s disease, when they need it. We are working through how the plan will articulate the changes for different professional groups.

The Department recognises the importance of maintaining high-quality services for people living with Parkinson’s disease. NHS England sets clear expectations of ICBs through national service specifications as well as guidance provided through initiatives like the Getting it Right First Time and RightCare Programmes to ensure equitable access to care for people with neurological conditions, including Parkinson’s. NHS England monitors ICB performance through planning guidance and assurance processes to ensure compliance with national standards and to prevent inappropriate service reductions.

The Department does not hold data on the number of neurologists or geriatricians with specialist training in Parkinson’s disease, nor does NHS England publish workforce projections at this level of granularity. Neurologists typically manage a wide range of conditions, including Parkinson’s, and geriatricians are trained to manage a broad range of complex health needs in older people. Workforce data is collected for the specialty as a whole rather than by sub-specialty.

As of August 2025, there were 2,010 full-time equivalent (FTE) doctors working in the specialty of neurology and 6,284 in geriatric medicine in National Health Service trusts and other organisations in England. This includes 1,025 FTE consultant neurologists and 1,687 FTE consultant geriatricians.

The Department does not hold specific data on the number of specialist Parkinson’s nurses currently working in the NHS in England. These roles are commissioned and managed locally by NHS trusts and integrated care boards (ICBs) as part of neurology and movement disorder services.

NHS England uses workforce modelling to establish potential future scenarios for both the supply of, and demand for, NHS workers across all specialties. In doing so, they analyse a range of factors, including population health trends, service utilisation patterns, and projected retirement and training rates. This modelling helps determine the number of training places required and informs long-term workforce planning, ensuring that specialties such as neurology and geriatric medicine have sufficient capacity to meet anticipated needs.

The Government will publish a 10 Year Workforce Plan to set out action to create a workforce ready to deliver the transformed service set out in the 10-Year Health Plan. It will ensure that the NHS has the right people in the right places, with the right skills to care for patients, including those with Parkinson’s disease, when they need it. We are working through how the plan will articulate the changes for different professional groups.

The Department recognises the importance of maintaining high-quality services for people living with Parkinson’s disease. NHS England sets clear expectations of ICBs through national service specifications as well as guidance provided through initiatives like the Getting it Right First Time and RightCare Programmes to ensure equitable access to care for people with neurological conditions, including Parkinson’s. NHS England monitors ICB performance through planning guidance and assurance processes to ensure compliance with national standards and to prevent inappropriate service reductions.

The Department does not hold data on the number of neurologists or geriatricians with specialist training in Parkinson’s disease, nor does NHS England publish workforce projections at this level of granularity. Neurologists typically manage a wide range of conditions, including Parkinson’s, and geriatricians are trained to manage a broad range of complex health needs in older people. Workforce data is collected for the specialty as a whole rather than by sub-specialty.

As of August 2025, there were 2,010 full-time equivalent (FTE) doctors working in the specialty of neurology and 6,284 in geriatric medicine in National Health Service trusts and other organisations in England. This includes 1,025 FTE consultant neurologists and 1,687 FTE consultant geriatricians.

The Department does not hold specific data on the number of specialist Parkinson’s nurses currently working in the NHS in England. These roles are commissioned and managed locally by NHS trusts and integrated care boards (ICBs) as part of neurology and movement disorder services.

NHS England uses workforce modelling to establish potential future scenarios for both the supply of, and demand for, NHS workers across all specialties. In doing so, they analyse a range of factors, including population health trends, service utilisation patterns, and projected retirement and training rates. This modelling helps determine the number of training places required and informs long-term workforce planning, ensuring that specialties such as neurology and geriatric medicine have sufficient capacity to meet anticipated needs.

The Government will publish a 10 Year Workforce Plan to set out action to create a workforce ready to deliver the transformed service set out in the 10-Year Health Plan. It will ensure that the NHS has the right people in the right places, with the right skills to care for patients, including those with Parkinson’s disease, when they need it. We are working through how the plan will articulate the changes for different professional groups.

The Department recognises the importance of maintaining high-quality services for people living with Parkinson’s disease. NHS England sets clear expectations of ICBs through national service specifications as well as guidance provided through initiatives like the Getting it Right First Time and RightCare Programmes to ensure equitable access to care for people with neurological conditions, including Parkinson’s. NHS England monitors ICB performance through planning guidance and assurance processes to ensure compliance with national standards and to prevent inappropriate service reductions.

The Department does not hold data on the number of neurologists or geriatricians with specialist training in Parkinson’s disease, nor does NHS England publish workforce projections at this level of granularity. Neurologists typically manage a wide range of conditions, including Parkinson’s, and geriatricians are trained to manage a broad range of complex health needs in older people. Workforce data is collected for the specialty as a whole rather than by sub-specialty.

As of August 2025, there were 2,010 full-time equivalent (FTE) doctors working in the specialty of neurology and 6,284 in geriatric medicine in National Health Service trusts and other organisations in England. This includes 1,025 FTE consultant neurologists and 1,687 FTE consultant geriatricians.

The Department does not hold specific data on the number of specialist Parkinson’s nurses currently working in the NHS in England. These roles are commissioned and managed locally by NHS trusts and integrated care boards (ICBs) as part of neurology and movement disorder services.

NHS England uses workforce modelling to establish potential future scenarios for both the supply of, and demand for, NHS workers across all specialties. In doing so, they analyse a range of factors, including population health trends, service utilisation patterns, and projected retirement and training rates. This modelling helps determine the number of training places required and informs long-term workforce planning, ensuring that specialties such as neurology and geriatric medicine have sufficient capacity to meet anticipated needs.

The Government will publish a 10 Year Workforce Plan to set out action to create a workforce ready to deliver the transformed service set out in the 10-Year Health Plan. It will ensure that the NHS has the right people in the right places, with the right skills to care for patients, including those with Parkinson’s disease, when they need it. We are working through how the plan will articulate the changes for different professional groups.

The Department recognises the importance of maintaining high-quality services for people living with Parkinson’s disease. NHS England sets clear expectations of ICBs through national service specifications as well as guidance provided through initiatives like the Getting it Right First Time and RightCare Programmes to ensure equitable access to care for people with neurological conditions, including Parkinson’s. NHS England monitors ICB performance through planning guidance and assurance processes to ensure compliance with national standards and to prevent inappropriate service reductions.

The Department does not hold data on the number of neurologists or geriatricians with specialist training in Parkinson’s disease, nor does NHS England publish workforce projections at this level of granularity. Neurologists typically manage a wide range of conditions, including Parkinson’s, and geriatricians are trained to manage a broad range of complex health needs in older people. Workforce data is collected for the specialty as a whole rather than by sub-specialty.

As of August 2025, there were 2,010 full-time equivalent (FTE) doctors working in the specialty of neurology and 6,284 in geriatric medicine in National Health Service trusts and other organisations in England. This includes 1,025 FTE consultant neurologists and 1,687 FTE consultant geriatricians.

The Department does not hold specific data on the number of specialist Parkinson’s nurses currently working in the NHS in England. These roles are commissioned and managed locally by NHS trusts and integrated care boards (ICBs) as part of neurology and movement disorder services.

NHS England uses workforce modelling to establish potential future scenarios for both the supply of, and demand for, NHS workers across all specialties. In doing so, they analyse a range of factors, including population health trends, service utilisation patterns, and projected retirement and training rates. This modelling helps determine the number of training places required and informs long-term workforce planning, ensuring that specialties such as neurology and geriatric medicine have sufficient capacity to meet anticipated needs.

The Government will publish a 10 Year Workforce Plan to set out action to create a workforce ready to deliver the transformed service set out in the 10-Year Health Plan. It will ensure that the NHS has the right people in the right places, with the right skills to care for patients, including those with Parkinson’s disease, when they need it. We are working through how the plan will articulate the changes for different professional groups.

The Department recognises the importance of maintaining high-quality services for people living with Parkinson’s disease. NHS England sets clear expectations of ICBs through national service specifications as well as guidance provided through initiatives like the Getting it Right First Time and RightCare Programmes to ensure equitable access to care for people with neurological conditions, including Parkinson’s. NHS England monitors ICB performance through planning guidance and assurance processes to ensure compliance with national standards and to prevent inappropriate service reductions.

The Department ran a consultation, Eligibility for Healthy Start for groups that have no recourse to public funds or are subject to immigration controls, which provided examples of the potential impacts of extending Healthy Start to families with no recourse to public funds. The consultation has now closed, and the Department is currently considering options following the consultation. Further information will be available in due course.

Our flu vaccination campaign started in September, and is helping to keep people out of hospital.

The UK Health Security Agency is also working closely with colleagues in NHS North West and local integrated care boards (ICBs). There continues to be sustained multi-agency communications and marketing across the localised area and work is ongoing to promote and amplify prevention measures. Work continues to encourage prevention through targeted communications using local data to both the public and stakeholders whilst work is ongoing, as in every winter season, to show trends locally to allow the local health family to act accordingly via shared data and intelligence.

The ICB has stepped up public messaging around getting the flu vaccine for eligible groups and the importance of choosing the right service. This has included promoting a bespoke winter campaign in the local area as well as press releases, social media, and broadcast interviews at a local and regional level.

Some local hospitals have made it mandatory for staff to wear a surgical mask in any areas with suspected or confirmed influenza patients, and those patients who are suspected as having influenza on triage may also be asked to wear a mask. Masks are also available to patients and relatives in waiting areas.

No assessment has been made. The independent review into the prevalence and support for mental health conditions, attention deficit hyperactivity disorder, and autism will examine the similarities and differences between these conditions, focusing on prevalence, prevention, treatment, and current challenges in clinical services.

It will assess how diagnosis, medicalisation, and treatment impact individual outcomes, including the risks and benefits of medicalisation, and will identify approaches to provide varied support models and pathways, both within and beyond the National Health Service, that promote prevention and early intervention alongside clinical care.

The report will include recommendations for responding to rising need, both within the Government and across the health system and wider public services.

Digital transformation is revolutionising access to healthcare by putting patients at the centre of a modern, personalised, and data-driven service. The goal is to empower individuals with greater choice, transparency, and control over their care, while helping to reduce systemic health inequalities and drive digital modernisation across the National Health Service.

There are a range of changes that improve patient access to appointments and avoid missed appointments. Steps that we are taking to improve access include:

• enabling patients in England to submit online consultation submissions for help from their general practitioners (GPs) via the NHS App or their GP’s website. In October 2025, eight million online consultation submissions were made;
• rolling out cloud-based telephony to GP services, improving access via phone lines for those who struggle with digital solutions. This includes time-saving features such as call-backs and diversion into specialist services. These changes are already reducing call waiting times and improving patient experience;
• improving the ability to manage conditions outside GPs to support more timely access to care, including through Pharmacy First and Digital Referrals initiatives; and
• offering outpatient electronic referrals through the NHS App with 100% of acute trusts now offering first outpatient electronic referrals through the NHS App, with 89% allowing patients to manage follow up appointments too, with 100% expected in 2026.

To avoid missed appointment we sent over 130 million appointment invitations and reminders via the NHS App in the last year, replacing paper letters and reducing delays. Digital reminders and the ability for patients to reschedule at the swipe of a button are helping to cut Did Not Attend rates, supporting elective recovery, and improving GP access. Analysis shows that these measures are contributing to reductions in hospital waiting lists and improving patient satisfaction.

We know that families and stakeholders will be frustrated by the withdrawal of the most recent 2023 Learning from Lives and Deaths of People with a Learning Disability and Autistic People (LeDeR) report, published in September 2025 by King’s College London. We apologise for the upset this has caused to families and loved ones, and we will make sure lessons are learned so that this cannot happen again. We remain committed to ensuring learning from LeDeR is shared and used to drive tangible service improvements.

The report was temporarily withdrawn after a technical issue was identified by NHS England after its publication. Some data used in the LeDeR report comes from Medical Certificate Cause of Death data. This was due to a technical issue related to a new automated process introduced in spring 2023, which meant that some of this data was not updated properly in the LeDeR dataset. This means that some data on cause of death was not included in the 2023 LeDeR report when it should have been, which has subsequently impacted some of the published analysis in the 2023 LeDeR report.

In line with ethical research and statistical practice, King’s College London has now withdrawn the report and has issued a notice setting out the reason why. An updated version is being prepared for publication in January 2026.

A correction has been applied to ensure that the specific automated processing error cannot happen again. NHS England is working with King’s College London to implement a more robust data checking protocol for the next LeDeR report, which will be an analysis of reviews of deaths for people who died in 2024 and whose deaths were notified to LeDeR in that year.

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring that medicines, medical devices, and blood components for transfusions on the market in the United Kingdom are safe, effective, and manufactured to the highest standards of quality. The Medical Devices Regulations 2002 establish the statutory framework that medical devices must meet in order to comply with these standards.

Optical appliances as medical devices must comply with requirements set out in the regulatuons, which include bearing the UKCA or CE marking on the packaging or labelling of the device. Manufacturers based outside of the United Kingdom must have a UK responsible person, and all devices must be registered with the MHRA prior to being placed on the market. Manufacturers or their UK representatives must also monitor use of these devices when used in the UK and report serious incidents to the MHRA.

The MHRA ensure that medical devices placed on the market and put into service in the UK meet these regulatory requirements by: assessing all allegations of non-compliance brought to us, using a risk-based system; monitoring the activity of UK approved bodies we designate to assess the compliance of manufacturers; and investigating medical devices as a result of adverse incident reports or intelligence indicating a potential problem.

If the MHRA considers that a product is breaching the medical devices regulations, typically, the MHRA Devices Compliance Unit will contact the manufacturer or, if the manufacturer is based outside of the UK, the UK Responsible Person, outlining the agency’s concerns and requesting further information with a view to bringing them into compliance.

If a manufacturer fails to co-operate with our requests and continues to place a non-compliant product on the market, or there is a serious risk to public health, the MHRA may consider using our enforcement powers. Guidance on how we enforce medical device regulations is available at the following link:

https://www.gov.uk/government/publications/report-a-non-compliant-medical-device-enforcement-process/how-mhra-ensures-the-safety-and-quality-of-medical-devices

In addition to our investigatory and enforcement activities, the MHRA maintain ongoing relationships with external stakeholders including major online selling platforms to address non-compliant listings of medical devices available on the UK market, including those listed on overseas websites. This collaboration typically involves reporting mechanisms and proactive engagement with external online platforms to identify, address and prevent non-compliant listings.

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring medicines, medical devices, and blood components for transfusion meet applicable standards of safety, quality, and efficacy. The MHRA rigorously assesses available data, including from the Yellow Card scheme, and seeks advice from the Commission on Human Medicines, the MHRA’s independent advisory committee, where appropriate, to inform regulatory decisions, including amending the product information.

The MHRA has received a total of eight United Kingdom reports through the Yellow Card scheme associated with the reaction term aphantasia, from 1 January 2021 up to and including 12 December 2025. The following table shows a yearly breakdown of reports associated with aphantasia received from 1 January 2021 up to and including 12 December 2025:

In addition, the following table shows a yearly breakdown of reports received by substance associated with aphantasia from 1 January 2021 up to and including 12 December 2025:

Please note that each report may list more than one suspect drug. Therefore, the total number of reports received cannot be accurately derived from the figures presented in the above table.

It is important to note that anyone can report to the MHRA’s Yellow Card scheme and the recording of these reports in the Yellow Card database does not necessarily mean that the adverse reactions have been caused by the suspect drug. Many factors must be considered in assessing causal relationships, including temporal association, the possible contribution of concomitant medication, and the underlying disease. We encourage reporters to report suspected adverse reaction reports. The reporter does not have to be sure of a causal association between the drug and the reactions, as a suspicion will suffice.

The number of reports received cannot be used as a basis for determining the incidence of a reaction, as neither the total number of reactions occurring, nor the number of patients using the drug, is known.

The Medicines and Healthcare products Regulatory Agency (MHRA) ensures that medical devices placed on the market and put into service in the United Kingdom meet these regulatory requirements by:

- assessing all allegations of non-compliance brought to us, using a risk-based system;

- monitoring the activity of the UK approved bodies we designated to assess the compliance of manufacturers; and

- investigating medical devices as a result of adverse incident reports or intelligence indicating a potential problem.

If the MHRA considers a product to be breaching the medical devices regulations, typically, the MHRA’s Devices Compliance Unit will contact the manufacturer or, if the manufacturer is based outside of the UK, The UK Responsible Person, outlining our concerns and requesting further information with a view to bringing them into compliance.

If a manufacturer fails to co-operate with our requests and continues to place a non-compliant product on the market, or there is a serious risk to public health, the MHRA may consider using our enforcement powers. Guidance on how we enforce medical device regulations can be accessed on the GOV.UK website, in an online only format.

In addition to our investigatory and enforcement activities, the MHRA maintains ongoing relationships with external stakeholders, including other Government enforcement agencies and major online selling platforms to address non-compliant listings of medical devices available on the UK market, including those listed on overseas websites. This collaboration typically involves reporting mechanisms and proactive engagement with external online platforms to identify, address, and prevent non-compliant listings.

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring that medicines, medical devices, and blood components for transfusions on the market in the United Kingdom are safe, effective, and manufactured to the highest standards of quality. The Medical Devices Regulations 2002 (MDR 2002) establish the statutory framework that medical devices must meet in order to comply with these standards.

Optical appliances as medical devices must comply with the MDR 2002, which include bearing the UKCA or CE marking on the packaging or labelling of the device. Manufacturers or their UK representatives must also monitor the use of these devices when used in the UK and report serious incidents to the MHRA. Allegations of deficiencies and incidents that do not meet these standards must be reported to the MHRA through the Yellow card scheme or informed though published guidance around enforcement and compliance.

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for the regulation of medicines for human use, medical devices, and blood products for transfusion in the United Kingdom. This includes applying the legal controls on the retail sale, supply, and advertising of medicines which are set out in the Human Medicines Regulations 2012.

Sourcing medicines from unregulated suppliers significantly increases the risk of getting a product which is either falsified or not authorised for use. Products purchased in this way will not meet the MHRA’s strict quality and safety standards and could expose patients to incorrect dosages or dangerous ingredients.

Public safety is the number one priority for the MHRA, and its Criminal Enforcement Unit works hard to prevent, detect, and investigate illegal activity involving medicines and medical devices and takes robust enforcement action where necessary. It works closely with other health regulators, customs authorities, law enforcement agencies, and private sector partners, including e-commerce and the internet industry to identify, remove, and block online content promoting the illegal sale of medicines and medical devices.

The MHRA seeks to identify and, where appropriate, prosecute online sellers responsible for putting public health at risk. Last year, the MHRA and its partners seized more than 17 million doses of illegally traded medicines, including those usually issued on prescription. Additionally, the MHRA has also disrupted thousands of links to websites and social media pages selling medical products to the public illegally.

The MHRA’s FakeMeds campaign provides advice to people in the UK who are considering buying medication online, outlining how products can be accessed from safe and legitimate source.

Anyone who believes they’ve had a side effect from a medicine, or who believes they’ve received falsified stock, can report it to the MHRA’s Yellow Card scheme.

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring that medicines, medical devices, and blood components for transfusions on the market in the United Kingdom are safe, effective, and manufactured to the highest standards of quality. The Medical Devices Regulations 2002 (MDR 2002) establish the statutory framework that medical devices must meet in order to comply with these standards.

Opthalmic medical devices must comply with the MDR 2002, which include bearing the UKCA or CE marking on the packaging or labelling of the device. Manufacturers or their UK representatives must also monitor use of these devices when used in the UK. Allegations of deficiencies that do not meet these standards must be reported to the MHRA through the Yellow card scheme or informed though published guidance, with further information available on the GOV.UK website.

The MHRA is not responsible for the movement of medical devices across borders.

NHS England is not currently doing a review of the issues raised by Health Services Safety Investigations Body regarding electronic patient records. NHS England will not manage the timetable for implementation of safety standards and best practices, as this falls to trusts, each of whom have their own statutory duty to deliver safe care.

The eligibility criteria for Section 117 applies to those who have been discharged from hospital following detention under the Mental Health Act, including those who have been remitted to prison. This is to help meet their needs and reduce the risk of their mental health condition worsening, which could lead to another hospital admission. Where prisoners are remitted back to prison, their right to receive Section 117 aftercare should be dealt with in the same way as it would be in the community, apart from any provisions which do not apply in custodial settings, such as direct payments and choice of accommodation. We do not hold centralised data on the number of prisoners receiving support under Section 117.

Reducing waiting lists is a key part of the Government’s Health Mission, and we are committed to cutting waiting times across all specialities, including gynaecology. We have committed to return to the National Health Service constitutional standard, that 92% of patients wait no longer than 18 weeks from referral to treatment, by March 2029.

We are making good progress, with waiting lists cut by over 230,000 since the Government came into office, including nearly 14,000 fewer waits for gynaecology treatment.

We also delivered 5.2 million additional appointments between July 2024 and June 2025, exceeding our pledge of two million. However, we know there is more to do, and have confirmed over £6 billion of additional capital investment to expand capacity across diagnostics, electives, and urgent care. This includes expanding the number of surgical hubs, which provide valuable and protected capacity across elective specialities, including gynaecology. As of November 2025, over half of the 123 operational elective surgical hubs in England provide gynaecology services.

The Elective Reform Plan, published in January 2025, also committed to:

• increasing the relative funding available to support gynaecology procedures with the largest waiting lists;
• ensuring that independent sector providers play a greater role in providing support for the most challenged specialities, such as gynaecology; and
• reforming and optimising clinical pathways across a number of specialities. In gynaecology, this includes supporting the delivery of innovative models offering patients care closer to home and piloting gynaecology pathways in community diagnostic centres for patients with post-menopausal bleeding.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

I refer the Hon. Member to the answers provided on 11 November to Questions 87614 and 87615. Otherwise, we do not hold data at this level of granularity.

I refer the Hon. Member to the answers provided on 11 November to Questions 87614 and 87615. Otherwise, we do not hold data at this level of granularity.

The Government acknowledges that urgent and emergency care performance has not consistently met expectations in recent years. We are committed to restoring waiting standards to those set out in the NHS Constitution by the end of this Parliament, as outlined in our Medium Term Planning Framework, which is available at the following link:

https://www.england.nhs.uk/wp-content/uploads/2025/10/medium-term-planning-framework-delivering-change-together-2026-27-to-2028-29.pdf

Basildon Hospital is part of Mid and South Essex NHS Foundation Trust. In the financial year 2024/25, 29.1% of patients at Mid and South Essex NHS Foundation Trust waited for more than four hours from arrival to admission, transfer or discharge.

We are putting significant funding into expanding urgent and emergency service access for those most in need, including new Urgent Treatment Centres and Same Day Emergency Care facilities. Nationally, this will mean 800,000 fewer accident and emergency patients waiting over four hours this year.

The information is available at the following link:

https://www.england.nhs.uk/statistics/statistical-work-areas/ae-waiting-times-and-activity/ae-attendances-and-emergency-admissions-2025-26/

Reducing waiting lists is a key part of the Government’s Health Mission, and we are committed to cutting waiting times across all specialities and integrated care boards (ICBs). We have committed to returning to the National Health Service constitutional standard, that 92% of patients wait no longer than 18 weeks from referral to treatment, by March 2029. We are making good progress, with waiting lists cut by over 230,000 since the Government came into office, including nearly 14,000 fewer waits for gynaecology treatment.

We also delivered 5.2 million additional appointments between July 2024 and June 2025, exceeding our pledge of two million. However, we know that there is more to do and have confirmed over £6 billion of additional capital investment to expand capacity across diagnostics, electives, and urgent care. This includes expanding the number of surgical hubs, which provide valuable and protected capacity across elective specialities, including gynaecology. As of November 2025, there are 123 operational elective surgical hubs in England, three of which are in the NHS Lancashire and South Cumbria ICB. Over half of the 123 provide gynaecology services. The Elective Reform Plan, published in January 2025, also committed to:

• increasing the relative funding available to support gynaecology procedures with the largest waiting lists;
• ensuring that independent sector providers play a greater role in providing support for the most challenged specialities, such as gynaecology; and
• reforming and optimising clinical pathways across a number of specialities. In gynaecology, this includes supporting the delivery of innovative models offering patients care closer to home and piloting gynaecology pathways in community diagnostic centres for patients with post-menopausal bleeding.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department does not hold data on the number of applicants, whether domestically trained or overseas trained, that were accepted or rejected for nursing and midwife positions with National Health Service providers. NHS trusts will undertake local processes to manage recruitment to nursing and midwifery vacancies.

NHS England publish monthly information on the annual numbers of nurses and midwives joining the NHS, including information on the self-reported nationality of these staff but this will not necessarily be the same as the place of training. Joiners’ data will include staff returning from breaks in service and is available at the following link:

https://digital.nhs.uk/data-and-information/publications/statistical/nhs-workforce-statistics

On 11 August 2025, the Government announced the Graduate Guarantee for nurses and midwives. The Guarantee will ensure there are enough positions for every newly qualified nurse and midwife in England. The package of measures will unlock thousands of jobs and will ensure thousands of new posts are easier to access by removing barriers for NHS trusts, creating opportunities for graduates and ensuring a seamless transition from training to employment.

The Department does not hold data on the number of applicants, whether domestically trained or overseas trained, that were accepted or rejected for nursing and midwife positions with National Health Service providers. NHS trusts will undertake local processes to manage recruitment to nursing and midwifery vacancies.

NHS England publish monthly information on the annual numbers of nurses and midwives joining the NHS, including information on the self-reported nationality of these staff but this will not necessarily be the same as the place of training. Joiners’ data will include staff returning from breaks in service and is available at the following link:

https://digital.nhs.uk/data-and-information/publications/statistical/nhs-workforce-statistics

On 11 August 2025, the Government announced the Graduate Guarantee for nurses and midwives. The Guarantee will ensure there are enough positions for every newly qualified nurse and midwife in England. The package of measures will unlock thousands of jobs and will ensure thousands of new posts are easier to access by removing barriers for NHS trusts, creating opportunities for graduates and ensuring a seamless transition from training to employment.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.